In the NINDS r-tPA trial (National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator),16,101 exclusion for rapidly improving symptoms aimed to avoid treating transient ischemic attacks. Here, PLAT is linked to stroke disorder.